<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991025</url>
  </required_header>
  <id_info>
    <org_study_id>21-152</org_study_id>
    <nct_id>NCT04991025</nct_id>
  </id_info>
  <brief_title>A Study of Chemotherapy and Certolizumab in People Who Have Lung Cancer That Can Be Treated With Surgery</brief_title>
  <official_title>Phase 2 Trial of Neoadjuvant Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore adding the study drug certolizumab to standard&#xD;
      chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy&#xD;
      more effective in shrinking the cancer. This study will examine whether adding certolizumab&#xD;
      to the usual treatment approach is better than, the same as, or worse than the usual approach&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants major pathologic response (MPR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To evaluate the major pathologic response (MPR) of participants with stage II-III lung cancers who receive treatment with neoadjuvant platinum-based chemotherapy + certolizumab pegol. Major pathologic response (MPR) is defined as 10% or less residual viable tumor after neoadjuvant therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Stage II</condition>
  <condition>Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.</description>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle</description>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.</description>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.</description>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab</intervention_name>
    <description>Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.</description>
    <arm_group_label>Participants with resectable stage II-III lung cancers.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Untreated stage II-III lung cancers with operable and resectable disease determined by&#xD;
             a thoracic surgeon&#xD;
&#xD;
          -  Histologic confirmation of disease at MSKCC&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function, as specified below:&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9 /L&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Platelets ≥ 100 x 10^9 /L&#xD;
&#xD;
          -  Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with&#xD;
             documented Gilbert's Syndrome)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for&#xD;
             patients with creatinine levels above institutional normal.&#xD;
&#xD;
          -  Negative PPD test&#xD;
&#xD;
          -  For women of child-bearing potential, negative pregnancy test within 14 days prior to&#xD;
             starting treatment&#xD;
&#xD;
          -  Men and women of childbearing age must be willing to use effective contraception while&#xD;
             on treatment and for at least 3 months thereafter&#xD;
&#xD;
          -  Presence of at least one site of measurable disease as defined by the Response&#xD;
             Evaluation Criteria in Solid Tumors 1.1&#xD;
&#xD;
          -  Ability to provide written, informed consent. Legally Authorized Representatives are&#xD;
             permitted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an FDA approved targeted therapy for patients with NSCLC harboring a&#xD;
             genomic aberration for which an FDA-approved targeted therapy is indicated&#xD;
&#xD;
          -  Hypersensitivity to platinum agents&#xD;
&#xD;
          -  Ongoing use of investigational agents or use of investigational agents within the last&#xD;
             four weeks&#xD;
&#xD;
          -  Prior use of TNF-α inhibitor&#xD;
&#xD;
          -  History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis&#xD;
&#xD;
          -  Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)&#xD;
&#xD;
          -  Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment&#xD;
             with the exception of thrush&#xD;
&#xD;
          -  Active tuberculosis or untreated, latent tuberculosis&#xD;
&#xD;
          -  If a patient has signs, symptoms, or a history suggestive of active tuberculosis,&#xD;
             evaluation by an infectious disease physician will be required and active tuberculosis&#xD;
             ruled-out prior to enrollment.&#xD;
&#xD;
          -  Acute or chronic Hepatitis B or C infection&#xD;
&#xD;
          -  Known HIV infection requiring antiretroviral medications and those with AIDS&#xD;
&#xD;
          -  Active herpes zoster infection&#xD;
&#xD;
          -  Non-healed infected skin ulcers&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within the past 12 months&#xD;
&#xD;
          -  Ongoing use of other immunosuppressive medications, including oral steroids and&#xD;
             excluding topical steroids&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Prior history of other malignancy with the exclusion of localized prostate cancer,&#xD;
             non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the&#xD;
             breast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Paik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Paik, MD</last_name>
    <phone>646-608-3759</phone>
    <email>paikp@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Jones, MD</last_name>
    <phone>212-639-6428</phone>
    <email>jonesd2@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-608-3759</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Untreated Lung Cancer</keyword>
  <keyword>resectable lung cancer</keyword>
  <keyword>operable lung cancer</keyword>
  <keyword>Certolizumab</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>21-152</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

